The phase 3 PROOF-HD trial demonstrates persistent benefits of pridopidine on function, cognition, and motor function through the 6 month open label extension in Huntington disease (HD) - Michal Geva; Ralf Reilmann; Andrew Feigin; Anne Rosser; Sandra Kostyk; Kelly Chen; Yael Cohen; Y Paul Goldberg; Michael R. Hayden (Neurotherapeutics)